These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 8558934

  • 1. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
    Maslak PG, Weiss MA, Berman E, Yao TJ, Tyson D, Golde DW, Scheinberg DA.
    Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
    [Abstract] [Full Text] [Related]

  • 2. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
    Hsu HC, Chiu CF, Tan TD, Chau WK, Tseng CS, Ho CH.
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Nov; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 7. Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
    Baek JH, Sohn SK, Kim DH, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ.
    Acta Haematol; 2007 Nov; 117(2):109-14. PubMed ID: 17135724
    [Abstract] [Full Text] [Related]

  • 8. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, Peaud PY, Martin C, Amadori S, Willemze R.
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
    Pierri I, Clavio M, Beltrami G, Cavaliere M, Lanza L, Miglino M, Canepa L, Pietrasanta D, Ballerini F, Quintino S, Gatto S, Celesti L, Carrara P, Varese P, Gobbi M.
    J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678
    [Abstract] [Full Text] [Related]

  • 15. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
    Archimbaud E, Fenaux P, Reiffers J, Cordonnier C, Leblond V, Travade P, Troussard X, Tilly H, Auzanneau G, Marie JP.
    Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
    Löwenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P, Fey M, Schouten H, de Greef G, Ferrant A, Kovacsovics T, Gratwohl A, Daenen S, Huijgens P, Boogaerts M, Dutch-Belgian Hemato-Oncology Cooperative Group, Swiss Group for Clinical Cancer Research.
    N Engl J Med; 2003 Aug 21; 349(8):743-52. PubMed ID: 12930926
    [Abstract] [Full Text] [Related]

  • 19. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Fabères C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P.
    Leukemia; 1996 Mar 21; 10(3):389-95. PubMed ID: 8642852
    [Abstract] [Full Text] [Related]

  • 20. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar 21; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.